| Document |
Document Title |
|
WO/2022/014433A1 |
The present invention pertains to: a compound represented by formula (I) (in the formula, R1 represents a hydroxyl group, a mercapto group, a C1-6-alkoxy group, a C1-6-haloalkoxy group, an amino group, a C1-6-alkyl amino group, or a di-C...
|
|
WO/2022/008639A1 |
The application relates to 2-imino-hexahydropyrimidin-4-one derivatives of formula (I) which are potent inhibitors of the growth and propagation of the Plasmodium falciparum parasite in human blood and thus useful for the treatment of ma...
|
|
WO/2022/005881A1 |
Disclosed herein are methods, compounds, and compositions for treating or preventing inflammasome-mediated diseases or conditions, including inflammasome-mediated lung diseases or conditions.
|
|
WO/2022/003712A1 |
The present invention described herein relates to a compound having Structure I for treating diseases and disorders for which inhibition or modulation of the Ubiquitin Ligase COP1 enzyme produces a physiologically beneficial response, in...
|
|
WO/2022/002116A1 |
The present invention provides a synthesis method for a phenylisoxazoline compound, comprising: synthesizing uracil first by taking 2-fluoro-4-chloro-5-methylaniline as a starting raw material, and then synthesizing an isoxazoline ring t...
|
|
WO/2022/002102A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of u...
|
|
WO/2021/260090A1 |
The invention relates to compounds of Formula (I) wherein X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5, and R6 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical com...
|
|
WO/2021/259815A1 |
The present invention provides compounds of formula I or II: wherein X1, X3, R1, R2, R3, R4 and R5 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufac...
|
|
WO/2021/223650A9 |
The present application relates to a nitrogen-containing compound. The structural formula of the nitrogen-containing compound is as shown in formula I, in which ring A and ring B are each independently selected from a benzene ring or a f...
|
|
WO/2021/256883A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound according to the present invention can be used in an organic material layer of an organic electroluminescent device,...
|
|
WO/2021/256881A1 |
The present invention relates to a novel compound having excellent light-emitting ability and an organic electroluminescent device comprising same, in which the compound according to the present invention is used in organic material laye...
|
|
WO/2021/254464A1 |
A substituted quinazoline compound, and a preparation method therefor, a pharmaceutical composition thereof, and a use thereof. Specifically, the present invention relates to a substituted quinazoline compound having BRK and/or BTK kinas...
|
|
WO/2021/256871A1 |
The present invention relates to a novel compound exhibiting excellent light-emitting performance and an organic electroluminescent device comprising same. The compound according to the present invention is used in an organic layer of an...
|
|
WO/2021/254920A1 |
Provided herein is a process for synthesis of intermediates for ipatasertib related to large scale manufacture of (R)-5-methyl-4-(piperazin-1-yl)-5,6-dihydro-7H-cyclopenta[d]
pyrimidin-7-one.
|
|
WO/2021/256880A1 |
The present invention relates to a novel compound having excellent light-emitting ability and an organic electroluminescent device comprising same. The compound according to the present invention can be used for the material of an organi...
|
|
WO/2021/255429A1 |
The invention includes a process for the synthesis of N,N-dimethyl-4-((6-oxopyrimidin-1(6H)- yl)methyl)benzamide and 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid, a process for 5 synthesising crystalline forms of N,N-dimethyl-4-((6-ox...
|
|
WO/2021/255436A1 |
• A composition comprising 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid, • 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid for use as a medicament, • 4-((6-oxopyrimidin-1(6H)-yl)methyl) benzoic acid for use in a method of trea...
|
|
WO/2021/250558A1 |
The invention provides an improved process for the preparation of fluoxastrobin and intermediates thereof. The present invention provides a process for the preparation of fluoaxastrobin, 4,6-dichloro-5-fluoro-pyrimidine and diethyl 2-chl...
|
|
WO/2021/250521A1 |
Provided herein is a compound of the Formula I: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and L are as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-as...
|
|
WO/2021/252680A1 |
Disclosed herein are certain 4-arylquinazoline derivatives of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating dis...
|
|
WO/2021/252475A1 |
Provided herein is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods ...
|
|
WO/2021/247634A1 |
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...
|
|
WO/2021/244560A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compoun...
|
|
WO/2021/244582A1 |
The present application provides a novel thyroid hormone β receptor agonist having better activity, selectivity or safety and represented by formula (I), and use thereof in preventing or treating a disease related to the β receptor ago...
|
|
WO/2021/247732A1 |
The present invention relates to compounds of formula I (I) as well as to the compounds of formula I for use as transmembrane serine protease 2 (TMPRSS2) inhibitors in the treatment of viral infections, such as e.g. corona virus infectio...
|
|
WO/2021/246713A1 |
The present specification relates to a compound of chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/245087A1 |
The present disclosure relates to heterocyclyl pyrimidine and heterocyclyl triazine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopat...
|
|
WO/2021/238835A1 |
The present invention relates to a crystal form C of (2E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quina
zolinyl]-4-(1-piperidinyl)-2-butenamide, and a preparation method therefor and a drug containing same. The crystal form C i...
|
|
WO/2021/238908A1 |
The present invention relates to a salt and a crystal form containing a heteroaryl derivative. The present invention specifically relates to a salt and a crystal form comprising a compound of general formula (I), a preparation method, an...
|
|
WO/2021/239643A1 |
The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositi...
|
|
WO/2021/236449A1 |
Disclosed herein are p38a mitogen-activated protein kinase inhibitors, pharmaceutical compositions thereof, and therapeutic methods of using the p38a mitogen-activated protein kinase inhibitors.
|
|
WO/2021/236775A1 |
The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein R1, R3, L, Y, and B1 are as defined in the specification. Compounds having Formula I are SHP2 protein degraders useful for the...
|
|
WO/2021/237004A1 |
The present disclosure encompasses novel solid state forms of Aprocitentan, Aprocitentan salts and Aprocitentan co-crystals, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2021/235283A1 |
The present invention provides: a radiation sensitive resin composition which is capable of exhibiting sensitivity, CDU performance and LWR performance at sufficient levels; and a method for forming a resist pattern. A radiation sensitiv...
|
|
WO/2021/228945A1 |
The present invention relates to the use of at least one compound of formula (I), or one of its pharmaceutically acceptable salts, for preventing and/or treating a disease caused by a nonsense mutation. It also relates to compounds of fo...
|
|
WO/2021/231726A1 |
The disclosure provides compositions and methods of quinoline, quinazolines, and pyrydylpyridines derivatives for the inhibition of ENPP1 modulators.
|
|
WO/2021/226814A1 |
Disclosed are a small-molecule compound SPAM1 for up-regulating a neuropeptide PACAP and a receptor PAC1-R thereof, and a preparation method therefor and an application thereof. The structure of the SPAM1 is as shown in formula (I), wher...
|
|
WO/2021/228734A1 |
The present disclosure relates to triazine and pyrimidine (thio)amide compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2021/224927A1 |
The invention in some embodiments thereof, relates to the field of compositions and/or pharmaceutical compositions comprising one or more biologically active compound, and is directed to methods of using same such as for treating an ApoL...
|
|
WO/2021/224802A1 |
The present invention provides a stable, liquid composition comprising: (a) a fungicidally effective amount of a compound of Formula I, and (b) a liquid carrier, wherein: (i) the composition comprises (a) a fungicidally effective and sub...
|
|
WO/2021/226629A1 |
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...
|
|
WO/2021/226260A1 |
The present invention provides crystalline forms of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-py
rimidine-2,4-dione, and methods of making and using the same.
|
|
WO/2021/226258A1 |
The present invention provides formulations of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-py
rimidine-2,4-dione, and methods of making and using the same.
|
|
WO/2021/225969A1 |
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disc...
|
|
WO/2021/225878A1 |
The present invention provides a compound of Formula (I): wherein R1 is hydrogen or methyl; and R2 is: or a pharmaceutically acceptable salt thereof, useful for treating pain, including chronic pain, chronic lower back pain, diabetic per...
|
|
WO/2021/226161A1 |
An improved process for preparing verdiperstat is disclosed. The process includes the steps of reacting a compound having formula or a salt thereof, wherein R is the same or different and is each independently a C1-C5 alkyl with 3-(dimet...
|
|
WO/2021/218588A1 |
The present application belongs to the field of organic light-emitting materials, and specifically relates to a nitrogen-containing compound, an electronic component using same and an electronic device. The nitrogen-containing compound h...
|
|
WO/2021/219513A1 |
The present application relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined in the claims. The compounds of for...
|
|
WO/2021/222888A1 |
The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogen...
|
|
WO/2021/219594A1 |
The invention relates to compounds of Formula (I) wherein X1, X2, X3, Y, R1, R2A, R2B, R3, and R4 are as described in the description; to their preparation, to pharmaceutically acceptable salts thereof, to pharmaceutical compositions con...
|
